BTK Inhibitors: An Emerging Target in Multiple Sclerosis - Evaluation (ID: i849-2) Question Title * 1. How many years have you been in practice? ≥21 11-20 1-10 <1 Question Title * 2. How many patients with MS do you manage each week? 1 to 10 11 to 25 26 or more I am not directly involved in patient care Question Title * 3. Please select the option that best describes your practice setting: Academic medical center Community medical center VA, DOD, or other government Managed care Research Pharmaceutical industry Question Title * 4. After participating in this activity, how confident are you in the management of patients with MS in your practice? Very confident Confident Neutral Little confidence No confidence Question Title * 5. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes If not committed or do not plan to make changes, please indicate reason Question Title * 6. Which of the following best describes the impact of this activity on your performance? I gained new strategies/skills/information I can apply to my area of practice I need more information before I can change my practice My practice is already consistent with the information presented This activity will not change my practice Question Title * 7. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply. Greater understanding of the rationale for BTK inhibition in the management of MS Increased awareness of the potential for improvements in MS treatment outcomes with BTK inhibition Improved knowledge of the mechanism of action of emerging BTK inhibitor therapies for MS treatment Greater knowledge of how these mechanisms may directly translate into therapeutic benefits for patients with MS Increased knowledge regarding clinical trial safety and efficacy data on emerging BTK inhibitors in MS Greater knowledge of how to monitor and manage the potential side effects of BTK inhibitor therapy Question Title * 8. What barriers do you see to making changes in your practice? Please select all that apply. Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement, or legal issues Conflicting guidelines or evidence Patient compliance and/or patient resource barriers Other (please specify) Question Title * 9. Please rate your level of agreement by checking the appropriate rating. After participating in today’s activity, I am now better able to: Strongly agree Agree Neutral Disagree Strongly disagree Improve knowledge of clinicians on the role of BTK inhibition in MS management Improve knowledge of clinicians on the role of BTK inhibition in MS management Strongly agree Improve knowledge of clinicians on the role of BTK inhibition in MS management Agree Improve knowledge of clinicians on the role of BTK inhibition in MS management Neutral Improve knowledge of clinicians on the role of BTK inhibition in MS management Disagree Improve knowledge of clinicians on the role of BTK inhibition in MS management Strongly disagree Describe the mechanisms of action for emerging BTK inhibitors Describe the mechanisms of action for emerging BTK inhibitors Strongly agree Describe the mechanisms of action for emerging BTK inhibitors Agree Describe the mechanisms of action for emerging BTK inhibitors Neutral Describe the mechanisms of action for emerging BTK inhibitors Disagree Describe the mechanisms of action for emerging BTK inhibitors Strongly disagree Recall available safety and efficacy data for emerging BTK inhibitors Recall available safety and efficacy data for emerging BTK inhibitors Strongly agree Recall available safety and efficacy data for emerging BTK inhibitors Agree Recall available safety and efficacy data for emerging BTK inhibitors Neutral Recall available safety and efficacy data for emerging BTK inhibitors Disagree Recall available safety and efficacy data for emerging BTK inhibitors Strongly disagree Question Title * 10. Please rate your level of agreement by checking the appropriate rating. Daniel S. Reich, MD, PHD effectively: Strongly agree Agree Neutral Disagree Strongly disagree Presented the material Presented the material Strongly agree Presented the material Agree Presented the material Neutral Presented the material Disagree Presented the material Strongly disagree Avoided commercial bias Avoided commercial bias Strongly agree Avoided commercial bias Agree Avoided commercial bias Neutral Avoided commercial bias Disagree Avoided commercial bias Strongly disagree Question Title * 11. The content presented: Strongly agree Agree Neutral Disagree Strongly disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly disagree Addressed my most pressing questions Addressed my most pressing questions Strongly agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly disagree Question Title * 12. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 13. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for MS: Question Title * 14. If you indicated that you perceived commercial bias or influence, please describe: Done
